Brief: Kronos Bio Announces First Patient Dosed in Phase 3 Study of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemi
06/12/2021 12:55
Dec 6 (Reuters) - Kronos Bio Inc KRON.O :
* KRONOS BIO ANNOUNCES FIRST PATIENT DOSED IN AGILITY PHASE
3
CLINICAL TRIAL OF ENTOSPLETINIB IN PATIENTS WITH NEWLY DIAGNOSED
NPM1-MUTATED ACUTE MYELOID LEUKEMIA
Source text for Eikon: ID:nGNX7szdqg
Further company coverage: KRON.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Kronos Bio
See all newsBrief: Kronos Bio Inc - Terminates Office Lease At 301 Binney Street - SEC Filing
Brief: Kronos Bio Inc - Enters Transition Agreement With Genentech
U.S. STOCKS ON THE MOVE - Ambarella, Dell, Nordstrom
U.S. STOCKS ON THE MOVE - Golden Ocean, Guess, Symbotic
U.S. STOCKS ON THE MOVE-HP, Urban Outfitters, 3D Systems